) recently presented morbidity and mortality data on pipeline
candidate, Opsumit, from a pivotal phase III study, SERAPHIN
(Study with an Endothelin Receptor Antagonist in Pulmonary
arterial Hypertension to Improve cliNical outcome), at the
European Respiratory Society Annual Congress.
The results from the trial (n=742) showed that the risk of a
morbidity/mortality event was cut by 45% in pulmonary arterial
hypertension (PAH) patients treated with Opsumit as compared to
those on placebo.It was found that the effects of Opsumit seen
earlier in the trial were sustained throughout.
Data from the study showed that Opsumit minimizes PAH related
risk of hospitalization and death by 50% and all-cause mortality
by 36% as compared to placebo.
The study revealed significant treatment effect in its
secondary outcome measures for Opsumit as compared to
We note that Actelion is looking to get Opsumit approved for
the treatment of patients suffering from PAH. Opsumit is
currently under review in the U.S., EU and other countries.
Apart from PAH, Opsumit is also being evaluated in a pivotal
phase III program in patients suffering from digital ulcers
associated with systemic sclerosis. Results from this study are
expected in 2014. In addition, Opsumit is being evaluated for the
treatment of glioblastoma (phase I).
Actelion currently carries a Zacks Rank #1 (Strong Buy). Other
stocks that look equally attractive include
Biogen Idec Inc
), which carry a Zacks Rank #1.
Gilead Sciences Inc.
) also looks well positioned with a Zacks Rank #2 (Buy).
AFFYMETRIX INC (AFFX): Free Stock Analysis
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
To read this article on Zacks.com click here.